{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:28:47Z","timestamp":1778336927679,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["C333-19-952061 EATRIS-TRI.SI"],"award-info":[{"award-number":["C333-19-952061 EATRIS-TRI.SI"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Methotrexate is widely prescribed for the treatment of moderate-to-severe psoriasis. As drug survival encompasses efficacy, safety, and treatment satisfaction, such studies provide insights into successful drug treatments in the real-life scenario. The objective was to define methotrexate drug survival and reasons for discontinuation, along with factors associated with drug survival, in a cohort of adult patients with moderate-to-severe plaque psoriasis. Materials and Methods: Data on methotrexate treatment were extracted from our institutional registry. Drug survival was estimated by Kaplan\u2013Meier analysis, and predictors of drug survival were analyzed by Cox proportional hazards regression. Results: We included 133 patients treated with methotrexate. Due to significant effects of the year of treatment initiation, drug survival analysis was performed for 117 patients who started methotrexate in 2010 or later. Median methotrexate drug survival was 11.0 months. Overall, 89% of patients discontinued treatment, with over half of these (51%) due to lack of efficacy. Significantly longer drug survival was seen for patients who discontinued treatment due to lack of efficacy versus drug safety (p = 0.049); when stratified by sex, this remained significant only for women (p = 0.002). The patient ABCC2 rs717620 genotype was significantly associated with drug survival in both univariate log-rank and multivariate Cox regression analyses, with variant T allele associated with longer drug survival (hazard ratio, 0.606; 95% confidence interval, 0.380\u20130.967; p = 0.036). Conclusions: We have identified the novel association of patient ABCC2 rs717620 genotype with methotrexate drug survival. This pharmacogenetic marker might thus help in the management of psoriasis patients in daily practice.<\/jats:p>","DOI":"10.3390\/medicina57101050","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T01:57:54Z","timestamp":1633917474000},"page":"1050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Polymorphism in Gene for ABCC2 Transporter Predicts Methotrexate Drug Survival in Patients with Psoriasis"],"prefix":"10.3390","volume":"57","author":[{"given":"Jasna","family":"Gr\u017eelj","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"},{"name":"Krka, d. d., Novo Mesto, \u0160marje\u0161ka cesta 6, 8000 Novo Mesto, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-1416","authenticated-orcid":false,"given":"Maru\u0161ka","family":"Marovt","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pij B.","family":"Marko","sequence":"additional","affiliation":[{"name":"Department of Dermatovenerology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irena","family":"Mlinari\u010d-Ra\u0161\u010dan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja","family":"Gmeiner","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alenka","family":"\u0160mid","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Ljubljana, A\u0161ker\u010deva cesta 7, 1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/ijd.14246","article-title":"Review of safety and efficacy of approved systemic psoriasis therapies","volume":"58","author":"Kaushik","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/1744666X.2015.1026894","article-title":"Systemic methotrexate for the treatment of psoriasis","volume":"11","author":"Puig","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2340\/00015555-2276","article-title":"Effectiveness of biologic and conventional systemic therapies in adults with chronic plaque psoriasis in daily practice: A systematic review","volume":"96","author":"Zweegers","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Carretero","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"West, J., Ogston, S., and Foerster, J. (2016). Safety and efficacy of methotrexate in psoriasis: A meta-analysis of published trials. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153740"},{"key":"ref_8","first-page":"1","article-title":"Drug survival studies in dermatology: Principles, purposes, and pitfalls","volume":"135","author":"Kievit","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: A systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/ddg.13152","article-title":"Drug survival rates and reasons for drug discontinuation in psoriasis","volume":"14","author":"Arnold","year":"2016","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/jdv.13682","article-title":"Survival of classic and biological systemic drugs in psoriasis: Results of the BIOBADADERM registry and critical analysis","volume":"30","author":"Dauden","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/09546634.2019.1597244","article-title":"Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: Prospective results from the SAHARA study","volume":"31","author":"Puig","year":"2020","journal-title":"J. Dermatolog. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2340\/00015555-2130","article-title":"Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis","volume":"95","author":"Shalom","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000452740","article-title":"Efficacy and survival of systemic psoriasis treatments: An analysis of the Swiss registry SDNTT","volume":"232","author":"Maul","year":"2016","journal-title":"Dermatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/jdv.15978","article-title":"Real-world comparative effectiveness of adalimumab, etanercept and methotrexate: A Swedish register analysis","volume":"34","author":"Svedbom","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjd.15305","article-title":"Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: Results of the prospective MTX-CAPTURE","volume":"177","author":"Otero","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Busger op Vollenbroek, F.T.M., Doggen, C.J.M., Janssens, R.W.A., and Bernelot Moens, H.J. (2018). Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194401"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/ijd.15628","article-title":"Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: A real-life multicenter study","volume":"60","author":"Karadag","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","article-title":"Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis","volume":"127","author":"Campalani","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2133.2008.08898.x","article-title":"Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms","volume":"160","author":"Warren","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/jdv.16440","article-title":"The impacts of gene polymorphisms on methotrexate in Chinese psoriatic patients","volume":"34","author":"Chen","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jdermsci.2018.06.009","article-title":"Genetic polymorphism predicting Methotrexate efficacy in Chinese patients with psoriasis vulgaris","volume":"93","author":"Kuang","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"111456","DOI":"10.1016\/j.biopha.2021.111456","article-title":"Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis","volume":"138","author":"Marko","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/jdv.16205","article-title":"Drug survival in patients with psoriasis is associated with the availability of biologic medications","volume":"34","author":"Shalom","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjd.18047","article-title":"Persistence of apremilast in moderate-to-severe psoriasis: A real-world analysis of 14 147 apremilast- and methotrexate-naive patients in the French National Health Insurance database","volume":"182","author":"Sbidian","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/09546634.2016.1273469","article-title":"Effectiveness and safety of Methotrexate in psoriasis: An eight-year experience with 218 patients","volume":"28","year":"2017","journal-title":"J. Dermatolog. Treat."},{"key":"ref_28","first-page":"3","article-title":"Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis","volume":"108","year":"2017","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/1346-8138.14270","article-title":"Effectiveness of and factors associated with clinical response to methotrexate under daily life conditions in Asian patients with psoriasis: A retrospective cohort study","volume":"45","author":"Pongparit","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/keaa399","article-title":"First-line csDMARD monotherapy drug retention in psoriatic arthritis: Methotrexate outperforms sulfasalazine","volume":"60","author":"Jacobs","year":"2021","journal-title":"Rheumatology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/17425255.2014.952630","article-title":"Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance","volume":"10","author":"Bruhn","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_33","first-page":"381","article-title":"Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia","volume":"24","author":"Zgheib","year":"2014","journal-title":"Pharm. Genom."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/08880018.2019.1705949","article-title":"Association of ABCC2 with levels and toxicity of methotrexate in Malaysian Childhood Acute Lymphoblastic Leukemia (ALL)","volume":"37","author":"Razali","year":"2020","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","article-title":"High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations","volume":"80","author":"Rau","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","first-page":"56","article-title":"Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex","volume":"7","author":"Haenisch","year":"2007","journal-title":"Pharm. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:08:33Z","timestamp":1760166513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["medicina57101050"],"URL":"https:\/\/doi.org\/10.3390\/medicina57101050","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,1]]}}}